ADVFN Logo

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

MRK Merck and Co Inc

129.26
1.14 (0.89%)
22 Feb 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Merck and Co Inc MRK NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
1.14 0.89% 129.26 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
128.00 127.65 129.72 129.26 128.12
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
20/2/202415:14EDGAR2Form 8-K - Current report
20/2/202405:45BWFDA Grants Priority Review to Merck's Application for..
15/2/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202415:40EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:30EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:24EDGAR2Form 144 - Report of proposed sale of securities
13/2/202415:50EDGAR2Form 144 - Report of proposed sale of securities
13/2/202415:48EDGAR2Form 144 - Report of proposed sale of securities
12/2/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202406:05PRNCAHealth Canada Approves KEYTRUDA® in combination with..
09/2/202415:06EDGAR2Form 144 - Report of proposed sale of securities
08/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202406:00PRNCAMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE..
07/2/202415:09EDGAR2Form 144 - Report of proposed sale of securities
05/2/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202405:33BWMerck Animal Health to Acquire Elanco’s Aqua Business
02/2/202415:35EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:09EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:08EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202405:39EDGAR2Form 8-K - Current report
01/2/202405:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
27/1/202409:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
26/1/202410:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26/1/202409:00BWMerck’s KEYTRUDA® (pembrolizumab) Significantly Improved..
25/1/202407:07DJNLava Therapeutics Shares Rise as Drug Set for Test With..
24/1/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202414:29EDGAR2Form SC 13G - Statement of acquisition of beneficial..
23/1/202413:44BWMerck Announces Second-Quarter 2024 Dividend
23/1/202405:05DJNSanofi to Buy Assets From Inhibrx in Deal Valued at Up to..
19/1/202405:45BWMerck to Hold Fourth-Quarter and Full-Year 2023 Sales and..
15/1/202407:15PRNUSMerck Animal Health's Fourth Veterinary Wellbeing Study..
12/1/202417:13DJNMerck's Keytruda Combined with Chemoradiotherapy Gets FDA..
12/1/202416:30BWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus..
09/1/202409:21DJNMerck on Track for Record High Close -- Data Talk
09/1/202405:12IHMARKETNEWSWall Street Highlights: HPE and Juniper Networks in..
08/1/202413:54DJNTrending: Johnson & Johnson and Merck & Co. Announce..
08/1/202407:45IHNWExciting New Cures Possible from GLP-1 Diabetes, Weight-Loss..

Su Consulta Reciente

Delayed Upgrade Clock

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

Support: (55) 4170 8128 | soporte@advfn.mx